Navigation Links
Diopsys Receives CE Mark for its VEP Vision Testing Systems
Date:11/2/2011

PINE BROOK, N.J., Nov. 2, 2011 /PRNewswire/ -- Diopsys, Inc. announced today that its Visual Evoked Potential (VEP) Vision Testing Systems have been awarded the CE mark. The company has begun a roll-out of its patented vision testing devices to EU customers.

Diopsys completed a rigorous inspection of its total quality system in order to qualify for CE status.  "Having the CE mark opens many opportunities for us to provide clinicians and patients across the EU access to our advanced VEP technology," says Joseph Fontanetta, CEO of Diopsys, "Our VEP devices are designed to be used in an office setting and our patented technology overcomes many limitations of traditional VEP devices. Testing times are much faster than older VEP devices and our reports are easier to interpret. We are proud to bring an operator-friendly, objective, functional vision test to patients in need."

Diopsys is the developer and marketer of the Diopsys® NOVA-VEP Vision Testing Systems utilized by ophthalmologists and optometrists to aid in the detection, diagnosis and treatment of vision disorders, including glaucoma, a disease affecting millions globally. The company has also developed and markets the Enfant® Pediatric VEP Vision Testing System, a device used to test for visual deficits, including amblyopia, in children as young as six months of age.

Visual Evoked Potentials (VEPs) are electrical signals that are a measure of the electrophysiological activity at the visual cortex. VEP results are a representation of the functional integrity of all levels of the visual pathway including the eye, retina, optic nerve, and visual cortex. This technology has been used for a variety of applications that involve neuro-visual disorders such as glaucoma, amblyopia, multiple sclerosis and diabetic retinopathy, among many others.(1,2,3,4 )

About Diopsys

Diopsys, Inc. (www.diopsys.com) is a medical instrumentation company dedicated to delivering high-quality, cost-effective preventative health care solutions. The company specializes in the development and marketing of patient-friendly, non-invasive vision testing equipment utilizing Visual Evoked Potential (VEP) technology.

References

1. Prata TS, Lima VC, De Moraes CG, Trubnik V, Derr P, Liebmann JM, Ritch R, Tello C. Short Duration Transient Visual Evoked Potentials in Glaucomatous Eyes. J Glaucoma. 2011 May 10. [Epub ahead of print]

2. Simon J, Siegfried J, Mills M, Calhoun J, Gurland J. A New Visual Evoked Potential System for Vision Screening in Infants and Young Children. Journal of AAPOS. 8.6 (2004): 549-554.


3. Garcia-Martin E, Pueyo V, Ara JR, Almarcegui C, Martin J, Pablo L, Dolz I, Sancho E, Fernandez FJ. Effect of optic neuritis on progressive axonal damage in multiple sclerosis patients. Mult Scler. 2011 Jul;17(7):830-7. Epub 2011 Feb 7.

4. Parisi V, Uccioli L. Visual electrophysiological responses in persons with type 1 diabetes. Diabetes Metab Res Rev. 2001 Jan-Feb;17(1):12-8.


'/>"/>
SOURCE Diopsys, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Diopsys, Inc. Launches New Website for Doctors and Patients, www.Diopsys.com
2. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
6. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
7. CryoCor Receives FDA Approval for Right Atrial Flutter
8. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
9. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
10. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
11. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... , April 24, 2017 Solentim, ... today announced the addition of a major new ... In-situ Plate Seeding,). The VIPS has been developed ... 384 well microplates as part of the process ... offers a simple and more reliable solution when ...
(Date:4/20/2017)... PLANO, Texas , April 20, 2017  Vivify ... via mobile devices, has been awarded a very significant ... care via EMRs to continual care via digital health. ... of key intellectual property and further secures Vivify,s position ... Vivify, launched in 2009, was the first company to ...
(Date:4/20/2017)... , April 20, 2017  RXi Pharmaceuticals Corporation ... therapeutics that address significant unmet medical needs, today ... the Company,s consumer product development program, based on ... Society for Investigative Dermatology (SID) 76 th ... and promote the sciences relevant to skin health ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... ... committed to raising awareness for Duchenne muscular dystrophy, and funding for Duchenne ... (cardiosphere-derived cells) Phase I/II HOPE clinical trial in Duchenne announced today. , ...
(Date:4/25/2017)... ... April 25, 2017 , ... Lake Park Dental is now accepting ... Invisalign® in Lutz, FL. With the help of this highly-effective, yet convenient system, ... potential complications, more discretion and less pain. , Drs. Sarah Jockin, Nicole Morganti, ...
(Date:4/25/2017)... ... April 25, 2017 , ... Buyers and sellers in the thriving ... and head shops –can’t help but be heartened by the industry’s current surge. But ... aptly described as “skunk smell.” At last they can simply, safely and effectively ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... healthcare products, is introducing Flexadin UCII, part of the EQUISTRO line, at this ... joint health in horses at the immunologic level. , The scientifically-developed Flexadin UCII ...
(Date:4/24/2017)... ... 24, 2017 , ... The Santana Telehealth Project was honored with the 2017 ... American Telemedicine Association’s annual conference, on April 23 in Orlando, FL. , “I am ... the lives of the poor and underserved in other parts of the world,” said ...
Breaking Medicine News(10 mins):